Clinical trials: FTD
Alzheimer Disease, Dementia With Lewy Bodies (DLB)
Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder
This is a retrospective observational study to evaluate the clinical utility of blood-based biomarkers in the diagnosis and management of patients with a neurodegenerative disease (ND) or mental disorder (MD).
- Conditions
- Alzheimer Disease, Dementia With Lewy Bodies (DLB), Frontotemporal Dementia (FTD), Major Depressive Disorder (MDD)
- Trial name
- Synapsing-BK (NCT07314190)
- Where
- Spain
- Volunteers
- 1,799 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Frontotemporal Dementia
Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia
This study will evaluate the effects on emotions and neural activity of a one time dose of intranasal oxytocin vs. placebo in patients with FTD and healthy controls.
- Trial name
- IEMO (NCT01937013)
- Testing
- Intranasal oxytocin, Saline Nasal Mist
- Where
- Canada
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Dementia
Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)
The purpose of this clinical trial is to test whether or not the medication amantadine is effective in reducing behavioral disturbances in patients with frontotemporal dementia.
- Trial name
- NCT00127114
- Testing
- Amantadine
- Where
- United States
- Sponsor
- Johns Hopkins University
Primary Progressive Aphasia
A Multimodal Approach for Clinical Diagnosis and Treatment of Primary Progressive Aphasia, MAINSTREAM ID:3430931
Primary Progressive Aphasia (PPA) is a syndrome due to different neurodegenerative disorders selectively disrupting language functions. PPA specialist care is underdeveloped.
- Trial name
- MAINSTREAM (NCT05730023)
- Testing
- Active tDCS, individualized language training
- Where
- 4 sites in Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Frontotemporal Lobar Degeneration, Amyotrophic Lateral Sclerosis
Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS)
The project focuses on C9orf72, the most frequent genetic form of frontotemporal dementias (FTD, or frontotemporal lobar degeneration, FTLD) and amyotrophic lateral sclerosis (ALS).
- Trial name
- PREV-DEMALS (NCT02590276)
- Testing
- characterization
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary Progressive Aphasia, Neurodegenerative Diseases
Home-Based Exercise in Primary Progressive Aphasia (HEPPA)
This pilot study aims to evaluate the feasibility of a novel home-based multicomponent exercise program in adults clinically diagnosed with Primary Progressive Aphasia
- Conditions
- Primary Progressive Aphasia, Neurodegenerative Diseases, Logopenic Progressive Aphasia, Semantic Dementia
- Trial name
- HEPPA (NCT06181500)
- Testing
- Home-based multicomponent exercise intervention program
- Where
- 2 sites in Canada
- Volunteers
- 13 people
- Sponsor
- Montreal Heart Institute
Niemann-Pick Disease, Type C
Early Access Program With Arimoclomol in US Patients With NPC
NPC is a rare, relentlessly progressive, neurological disease and associated with serious morbidity and shortened life expectancy.
- Trial name
- NCT04316637
- Testing
- Arimoclomol
- Where
- 13 sites in United States
- Sponsor
- ZevraDenmark
Alzheimer's Disease
Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized
Tau pathology and tangles have been associated with cognitive dysfunction causing neurodegeneration. AD, the most abundant tauopathy is characterized by amyloid plaques and tau tangles.
- Trial name
- NCT01403519
- Where
- Israel
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Niemann-Pick Type C Disease, GM1 Gangliosidosis
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in…
- Conditions
- Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
- Trial name
- NCT07054515
- Testing
- AZ-3102
- Where
- 39 sites in United States, Argentina and 15 more
- Volunteers
- 147 people
- Sponsor
- Azafaros B.V.
Progressive Supranuclear Palsy (PSP), Healthy Participants
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
This clinical study is being conducted to learn more about two new imaging drugs, called [18F]ABBV-964i and [18F]ABBV-965i, which are designed to help doctors see changes in the brain related to a condition called Progressive…
- Trial name
- NCT07348276
- Testing
- [18F]ABBV-964i, [18F]ABBV-965i, Lead Candidate
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Invicro
Amyotrophic Lateral Sclerosis
The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study
Pre-fALS is a prospective natural history and biomarker study of people not yet affected with ALS, but who are at genetic risk for developing ALS.
- Trial name
- Pre-fALS (NCT00317616)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Miami
Primary Progressive Aphasia, Semantic Dementia
Primary Progressive Aphasia Multicomponent Language Treatment Study
The goal of this clinical trial is to learn if a speech-language telerehabilitation helps improve communication in people with primary progressive aphasia (PPA), a form of dementia that affects speech and language.
- Conditions
- Primary Progressive Aphasia, Semantic Dementia, Semantic Memory Disorder, Logopenic Progressive Aphasia
- Trial name
- NCT06649084
- Testing
- Multicomponent Lexical Retrieval Training (Multi-LRT), Multicomponent Video Implemented Script Training in Aphasia (Multi-VISTA), Multicomponent Communication Partner Training (Multi-CPT)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Texas at Austin
Semantic Dementia
Evaluation of a Transcranial Stimulation With Direct Current on Language Disorders in Semantic Dementia
Within the spectrum of fronto-temporal lobar degeneration (FTLD) semantic dementia (SD) causes profound language dysfunction. SD damages semantic processing typically in the temporal poles (anterior temporal lobes, ATL).
- Trial name
- STIM-SD (NCT03481933)
- Testing
- Transcranial stimulation
- Where
- 2 sites in France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Aphasia, Primary Progressive
Effects of Transcranial Direct Current Stimulation (tDCS) on Inhibition and Brain Function in Primary Progressive Aphasia
Primary progressive aphasia (PPA) is a focal dementia characterized by primary impairment of language abilities and functional disturbances associated with language.
- Trial name
- Stim-APHA (NCT06473714)
- Testing
- tDCS
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Frontotemporal Dementia, Behavioral Variant
Intranasal Insulin in Frontotemporal Dementia (FTD)
This project will study intranasal (IN) insulin in Frontotemporal dementia (FTD) in 12 patients. Study Investigators aim to evaluate the feasibility of the EXAMINER cognitive battery as a cognitive outcome measure in FTD, the…
- Trial name
- NCT04115384
- Testing
- Novolin-R insulin
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
Frontotemporal Dementia, Caregiver Burden
STELLA-FTD: Examination of a Behavior Change Intervention for FTD Family Care Partners
The purpose of this nationwide study is to test STELLA-FTD (Support via Telehealth: Living and Learning with Advancing Alzheimer's Disease)-FTD, an intervention to specifically address the needs of family Care Partners of persons…
- Conditions
- Frontotemporal Dementia, Caregiver Burden, Primary Progressive Aphasia (PPA), Corticobasal Syndrome
- Trial name
- STELLA-FTD (NCT06613204)
- Testing
- STELLA-FTD Control, STELLA-FTD Test
- Where
- United States
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Amyotrophic Lateral Sclerosis
Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders
The purpose of this study is to collect CSF and blood samples that can be used in future research studies to identify potential biomarkers in blood and cerebrospinal fluid (CSF) collected in Amyotrophic Lateral Sclerosis (ALS)…
- Trial name
- NCT05116943
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Primary Progressive Aphasia
HDtDCS in Logopenic Variant PPA: Effects on Language and Neural Mechanisms
This study aims to evaluate the effectiveness of a therapy called High-Definition Transcranial Direct Current Stimulation (HD-tDCS) for the treatment of the language deficits experienced by people with a type of Primary…
- Trial name
- NCT03805659
- Testing
- HD-tDCS
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Medical College of Wisconsin
Corticobasal Syndrome, Progressive Supranuclear Palsy
Diagnosing Frontotemporal Lobar Degeneration
To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromes
- Conditions
- Corticobasal Syndrome, Progressive Supranuclear Palsy, Behavioral Variant Frontotemporal Dementia, Semantic Dementia
- Trial name
- NCT02964637
- Testing
- Observational Study
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Stroke, Stroke (CVA) or TIA
The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)
Stroke is a major cause of death and disability worldwide, frequently resulting in persistent cognitive deficits among survivors.
- Conditions
- Stroke, Stroke (CVA) or TIA, Dementia, Vascular, Cerebrovascular Disorders
- Trial name
- IC3 (NCT05885295)
- Testing
- MRI brain, Blood tests, cognitive assessments
- Where
- United Kingdom
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Imperial College London